US judge dismisses FTC (Federal Trade Commission) fraud case against VISX
This article was originally published in Clinica
A US judge has ordered the dismissal of the Federal Trade Commission's patent fraud case against ophthalmic laser company VISX. The ruling supports an earlier decision where the judge had found in favour of VISX regarding three patents. Shares in VISX rose over 27% on the news.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.